chartexchange

Nuvation Bio to broaden Phase III glioma trial into Europe

Clinical Trials Arena | Oct 30, 2026 5:37 AM EDT

Nuvation Bio is set to expand its pivotal Phase III SIGMA trial into Europe to evaluate safusidenib in patients with IDH1-mutant glioma.
The post Nuvation Bio to broaden Phase III glioma trial into Europe appeared first on Clinical Trials Arena .

Read original article